It is therefore explicitly speculated that these metabolites might also immunomodulate response rates to ICI therapy [24]; a speculation that is corroborated by a recent study reporting oral supplementation of DAT to boost cancer immunotherapy with anti-CTLA4 which was dependent on IFN-I signaling in tumor-bearing mice [25]. Here, CTLA4 is linked to neoplasm.